Omnicell, Inc. (OMCL) Receives $47.00 Consensus PT from Brokerages

Omnicell, Inc. (NASDAQ:OMCL) has been given an average recommendation of “Buy” by the twelve research firms that are covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $47.00.

Several equities analysts have recently issued reports on the company. Zacks Investment Research raised Omnicell from a “sell” rating to a “hold” rating in a report on Tuesday, July 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $47.00 target price (up from $43.00) on shares of Omnicell in a report on Tuesday, June 13th. BidaskClub raised Omnicell from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 10th. ValuEngine raised Omnicell from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, TheStreet lowered Omnicell from a “b-” rating to a “c+” rating in a report on Thursday, May 4th.

ILLEGAL ACTIVITY NOTICE: “Omnicell, Inc. (OMCL) Receives $47.00 Consensus PT from Brokerages” was published by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/2723803/omnicell-inc-omcl-receives-47-00-consensus-pt-from-brokerages.html.

Omnicell (OMCL) traded up 0.47% during mid-day trading on Friday, hitting $43.10. The stock had a trading volume of 115,126 shares. The stock’s market cap is $1.60 billion. The firm’s 50-day moving average price is $42.12 and its 200-day moving average price is $38.65. Omnicell has a 1-year low of $30.35 and a 1-year high of $44.60.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, May 4th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.36. The company had revenue of $150.90 million during the quarter, compared to analyst estimates of $152.63 million. Omnicell had a positive return on equity of 2.66% and a negative net margin of 1.45%. Omnicell’s quarterly revenue was down 12.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.35 earnings per share. On average, equities analysts expect that Omnicell will post $1.28 earnings per share for the current year.

In other Omnicell news, VP J Christopher Drew sold 10,625 shares of the stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $40.97, for a total transaction of $435,306.25. Following the sale, the vice president now owns 152,057 shares in the company, valued at $6,229,775.29. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Dan S. Johnston sold 16,400 shares of the stock in a transaction on Friday, May 19th. The stock was sold at an average price of $40.67, for a total value of $666,988.00. Following the sale, the executive vice president now owns 61,696 shares in the company, valued at approximately $2,509,176.32. The disclosure for this sale can be found here. In the last quarter, insiders sold 101,000 shares of company stock worth $4,221,001. 3.75% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. increased its stake in Omnicell by 139,475.2% in the first quarter. BlackRock Inc. now owns 4,487,343 shares of the company’s stock valued at $182,412,000 after buying an additional 4,484,128 shares in the last quarter. Vanguard Group Inc. increased its stake in Omnicell by 5.5% in the first quarter. Vanguard Group Inc. now owns 1,860,299 shares of the company’s stock valued at $75,622,000 after buying an additional 97,345 shares in the last quarter. Champlain Investment Partners LLC increased its stake in Omnicell by 6.2% in the first quarter. Champlain Investment Partners LLC now owns 1,698,140 shares of the company’s stock valued at $69,029,000 after buying an additional 99,075 shares in the last quarter. Conestoga Capital Advisors LLC increased its stake in Omnicell by 12.9% in the first quarter. Conestoga Capital Advisors LLC now owns 1,513,866 shares of the company’s stock valued at $61,539,000 after buying an additional 172,642 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Omnicell by 11.0% in the first quarter. Bank of New York Mellon Corp now owns 1,190,691 shares of the company’s stock valued at $48,401,000 after buying an additional 118,201 shares in the last quarter.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.